Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Bridgewater Associates LP

Bridgewater Associates LP increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating) by 10.0% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 101,494 shares of the medical device company’s stock after purchasing an additional 9,244 shares during the quarter. Bridgewater Associates LP’s holdings in Tandem Diabetes Care were worth $6,007,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackRock Inc. increased its position in Tandem Diabetes Care by 0.8% during the 1st quarter. BlackRock Inc. now owns 6,531,074 shares of the medical device company’s stock worth $759,496,000 after purchasing an additional 52,436 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Tandem Diabetes Care by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 6,306,724 shares of the medical device company’s stock worth $733,408,000 after acquiring an additional 146,577 shares during the period. Invesco Ltd. boosted its holdings in Tandem Diabetes Care by 7.1% in the 1st quarter. Invesco Ltd. now owns 2,080,173 shares of the medical device company’s stock worth $241,904,000 after acquiring an additional 137,202 shares during the period. State Street Corp boosted its holdings in Tandem Diabetes Care by 3.6% in the 1st quarter. State Street Corp now owns 1,708,030 shares of the medical device company’s stock worth $198,627,000 after acquiring an additional 59,778 shares during the period. Finally, Champlain Investment Partners LLC boosted its holdings in Tandem Diabetes Care by 3.7% in the 1st quarter. Champlain Investment Partners LLC now owns 1,541,325 shares of the medical device company’s stock worth $179,241,000 after acquiring an additional 54,812 shares during the period. Institutional investors and hedge funds own 95.28% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TNDM. Lake Street Capital decreased their price target on Tandem Diabetes Care from $150.00 to $60.00 in a report on Thursday, November 3rd. Cowen decreased their price target on Tandem Diabetes Care from $107.00 to $61.00 in a report on Thursday, November 3rd. Wells Fargo & Company upgraded Tandem Diabetes Care from an “underweight” rating to an “equal weight” rating and set a $43.00 price target for the company in a report on Tuesday, November 15th. Raymond James decreased their price target on Tandem Diabetes Care from $92.00 to $52.00 and set an “outperform” rating for the company in a report on Friday, November 4th. Finally, Cowen decreased their price target on Tandem Diabetes Care from $107.00 to $61.00 in a report on Thursday, November 3rd. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $76.93.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock opened at $39.55 on Thursday. The stock has a 50 day moving average of $48.19 and a 200-day moving average of $55.47. Tandem Diabetes Care, Inc. has a 52 week low of $33.51 and a 52 week high of $155.86. The company has a current ratio of 4.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.67.

Tandem Diabetes Care Company Profile

(Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.